AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Natural History of Type 1 Interferonopathies: Insights From a European Cohort

Recruitingn/aAges any - anyAllImagine Institute
💬

In plain words

What the trial is, and whether it could suit you

Type I interferonopathies are rare autoinflammatory disorders caused by genetic defects and associated with significant morbidity and mortality. These diseases are refractory to conventional immunosuppressive therapies. They typically occur in childhood, although disease onset in adulthood has been observed. The clinical spectrum is wide and mainly involves the central nervous system. Joint involvement is also common, and more rarely, haematological features such as cytopenias or immunodeficiency may be observed. Nearly all patients show consistent over-activation of the type I IFN pathway, as evidenced, the expression of IFN-stimulated genes, the so-called 'interferon signature'. To date, the natural history of interferonopathies remains unclear. In this context, the establishment of a natural history of type I interferonopathy in patients is proposed to elucidate the pathophysiologic

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * Genetically confirmed patient with type I interferonopathy * Patient affiliated to a social security scheme or beneficiary of such a scheme. Exclusion Criteria: \- Opposition of the patient and/or parental authority if the patient is a minor, to participation in the study.
💊

What it tests

  • Not listed
📍

Where

32 sites
Medical University Innsbruck
Innsbruck, Austria
Antwerp University Hospital
Antwerp, Belgium
Children's Hospital Zagreb
Zagreb, Croatia
Motol University Hospital
Prague, Czechia
CHU d'Angers
Angers, France
Hôpital de Mercy - CHR Metz Thionville
Ars-Laquenexy, France
CHU de Besançon
Besançon, France
CHU de Bordeaux
Bordeaux, France

…and 24 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy